ChromaDex Corp (NAS:CDXC)
$ 2.82 0.03 (1.08%) Market Cap: 213.02 Mil Enterprise Value: 185.81 Mil PE Ratio: 0 PB Ratio: 7.23 GF Score: 74/100

Chromadex Corp KOL Webinar on the Transforming Benefits of Nicotinamide Riboside (NR) Transcript

Jul 20, 2022 / 03:00PM GMT
Release Date Price: $1.92 (+13.61%)
Tara Sobierajski

Good morning, and welcome to the ChromaDex KOL Webinar. (Operator Instructions) This call is being recorded and a replay will be made available on the ChromaDex website following the conclusion of the event. I'd now like to turn the call over to your host, Robert Fried, Chief Executive Officer of ChromaDex. Please go ahead, Robert.

Robert N. Fried
ChromaDex Corporation - CEO & Director

Thank you so much. Good morning, everyone, and thank you for joining us on today's KOL webinar on the transformational benefits of nicotinamide riboside, also referred to as NR or Niagen for short.

For those of you whom I've not had the pleasure of meeting, it's nice to meet you. My name is Rob Fried, and I'm the CEO of ChromaDex. ChromaDex is the leading bioscience company dedicated to healthy aging and research on the many benefits of nicotinamide riboside, which is by far the most efficient precursor to nicotinamide adenine dinucleotide or NAD.

NAD is the mission-critical coenzyme to cellular metabolism and declines naturally as we age.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot